GSK — GSK plc

—
NYSE · Health Care · Pharmaceuticals · CIK 1131399 · United Kingdom
Last close
$49.24
Market Cap
$98.62B
52W High
$60.11
52W Low
$38.11
ADV30
2,948,200
Next earnings
2026-10-28

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — — — —
Mar 2026 7,629,000,000 5,754,000,000 2,293,000,000 1,737,000,000 62,869,000,000 3,442,000,000 45,447,000,000
Dec 2025 8,618,000,000 5,961,000,000 1,506,000,000 636,000,000 61,118,000,000 3,150,000,000 45,162,000,000
Sep 2025 8,547,000,000 6,289,000,000 2,593,000,000 2,013,000,000 61,339,000,000 3,296,000,000 45,587,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$8,331,000,000
Investing CF
$-4,719,000,000
Financing CF
$-4,048,000,000
CapEx
$-3,000,000,000
Dividends Paid
$-2,666,000,000
Buybacks
$-1,203,000,000
EPS Diluted TTM
$2.36
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$11,464,000,000
Inventory
$6,282,000,000
Receivables
—
ST Investments
$1,000,000
EBIT TTM
$6,594,000,000
Pretax Income TTM
$5,904,000,000
Interest Exp TTM
$690,000,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$33,202,999,296
EBITDA
$10,817,999,872
Free Cash Flow
$3,482,625,024
Enterprise Value
$111,147,458,560
Total Cash
$3,105,999,872
Total Debt
$18,293,000,192
Shares Out
2,002,805,623
Trailing EPS
$3.19
Book Value
$11.91
ROE
33.4%
ROA
10.0%
Div Yield
3.78%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 32,667,000,000 8,338,000,000 5,716,000,000 61,118,000,000 45,162,000,000 16,377,000,000 7,741,000,000
Dec 2024 31,376,000,000 5,542,000,000 2,575,000,000 59,463,000,000 46,377,000,000 13,671,000,000 6,554,000,000
Dec 2023 30,328,000,000 7,345,000,000 4,928,000,000 59,005,000,000 46,210,000,000 13,347,000,000 6,768,000,000
Dec 2022 29,324,000,000 6,729,000,000 14,956,000,000 60,146,000,000 50,050,000,000 10,598,000,000 7,403,000,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$4.98

Max Pain — expiry 2026-11-20

max pain strike: $50.00 · spot: $49.53 · call oi: 9,639 · put oi: 3,174
Expected Move to 2026-11-20: ±$4.22 (8.53%) — implied range $45.30 – $53.75 · ATM straddle on $50.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SNY Sanofi $98.51B $41.11 —
REGN REGENERON PHARMACEUTICALS, INC. $79.70B $788.04 —
BMY BRISTOL MYERS SQUIBB CO $128.41B $62.86 —
NVO NOVO NORDISK A S $129.75B $38.80 —
VRTX VERTEX PHARMACEUTICALS INC / MA $133.37B $526.19 —

News headlines (Yahoo Finance, 1h cache)

Berenberg Turns Bullish on GSK as its $750 Million Deal Adds to Pipeline Momentum
2026-09-24 23:08 · Yahoo
GSK Adds Another Cancer Drug in a $750 Million Deal. Is its Oncology Bet Getting Bigger?
2026-09-24 22:41 · Yahoo
GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity
2026-09-24 20:59 · Yahoo
GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape
2026-09-23 10:02 · Yahoo
ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy
2026-09-21 09:00 · Yahoo
GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
2026-09-15 15:22 · Yahoo
GSK Cuts 641 Jobs in Vaccine Manufacturing Restructuring
2026-09-15 14:23 · Yahoo
GSK splashes up to $750m on experimental cancer therapy
2026-09-15 07:12 · Yahoo
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
2026-09-14 15:14 · Yahoo
$3.3 Million in New Philanthropic Commitments for Good Jobs Western North Carolina from The Rockefeller Foundation, John M. Belk Endowment, and NC GSK Foundation
2026-09-24 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.